Log in to search using one of your social media accounts:

 

Amylyx begins dosing in Phase II trial of AMX0035 for ALS

Amylyx Pharmaceuticals has begun dosing patients in the Phase II CENTAUR clinical trial of its therapeutic candidate, AMX0035, to treat those with amyotrophic lateral sclerosis (ALS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

The objective of this study is to assess the changes in CMAP scan from abductor pollicis brevis (APB) and abductor digiti minimi (ADM) muscles during the diagnosis and follow up period in amyotrophic lateral sclerosis (ALS) patients.
Source: Clinical Neurophysiology - Category: Neuroscience Authors: Source Type: research
To study inter- and intra-rater agreement on diagnostic criteria for amyotrophic lateral sclerosis (ALS).
Source: Clinical Neurophysiology - Category: Neuroscience Authors: Source Type: research
Loss of motor units (MUs) is the primary disease process in degenerative motor neuron diseases like amyotrophic lateral sclerosis (ALS). Reinnervation can compensate for MU loss. The net result is a reduced number of MUs, and increased MU size. The assessment of the number and size of MUs will be essential to study disease progression, and to study the efficacy of treatment.
Source: Clinical Neurophysiology - Category: Neuroscience Authors: Source Type: research
To compare the sensitivity of MUNE methods to quantitative motor unit potential (MUP) analysis in amyotrophic lateral sclerosis (ALS).
Source: Clinical Neurophysiology - Category: Neuroscience Authors: Source Type: research
Peak ratio analysis is a quantitative way of analyzing interference pattern by turns-amplitude analysis. We aimed in this study to compare the sensitivities of peak ratio analysis and quantitative motor unit potential (MUP) analysis in detecting chronic neurogenic changes in amyotrophic lateral sclerosis (ALS).
Source: Clinical Neurophysiology - Category: Neuroscience Authors: Source Type: research
Denervation causes increased echo intensity (EI) and decreased muscle thickness (MT) on muscle ultrasound (MUS). Chronic inflammatory demyelinating polyneuropathy (CIDP) does not present with denervation unless secondary axonal degeneration occurs. Hence, few MUS changes would occur compared to amyotrophic lateral sclerosis (ALS). The abductor pollicis brevis, abductor digiti minimi, and first dorsal interosseous muscles of 12 patients with CIDP and 13 patients with ALS were examined. There were no significant differences in Medical Research Council scales of each muscle between the CIDP and ALS group.
Source: Clinical Neurophysiology - Category: Neuroscience Authors: Source Type: research
The aim of the study is to evaluate the diagnostic value of triple stimulation technique (TST) and cortical excitability studies as markers of upper motor neuron degeneration in ALS patients and to compare the extent of electrophysiological changes in abductor pollicis brevis (APB) and abductor digiti minimi (ADM) muscles.
Source: Clinical Neurophysiology - Category: Neuroscience Authors: Source Type: research
Repeater F-waves (Freps) were seen in patients with amyotrophic lateral sclerosis (ALS). The factors implicated for the presence and frequency of Freps were loss of the motor neurons and the changes in their excitability. The aim of this study was to assess the Freps in ALS patients and to compare their frequencies in thenar and hypothenar muscles.
Source: Clinical Neurophysiology - Category: Neuroscience Authors: Source Type: research
ALS is a progressive neurodegenerative disease. Our aim was to examine the correlation of the severity of symptoms and the findings of electromyography (EMG), electroneurography (ENG) and to find parameters in estimating prognosis.
Source: Clinical Neurophysiology - Category: Neuroscience Authors: Source Type: research
Electromyographic (EMG) abnormalities that reveal denervation and reinnervation caused by lower motor neuron degeneration do not reflect the number of motor units that determines muscle strength. Consequently, motor unit activity potential (MUAP) parameters do not reflect muscle dysfunction.
Source: Clinical Neurophysiology - Category: Neuroscience Authors: Source Type: research
More News: ALS | Clinical Trials | Pharmaceuticals